US-based biopharmaceutical company Stealth BioTherapeutics has initiated its Phase I ReCLAIM study of elamipretide to treat intermediate, dry age-related macular degeneration (AMD).

The company's lead candidate elamipretide is an investigational drug developed to modify disease by preserving energetics and restoring normal energy production in mitochondria, while decreasing oxidative stress.

The Phase I open-label ReCLAIM study is being conducted to determine the safety and tolerability of a daily subcutaneous injections of elamipretide to treat age-related macular degeneration.

AMD is a progressive eye condition causing severe vision loss as it attacks the macula of the eye, where the sharpest central vision occurs.

Dry AMD triggers breakdown or thinning of the retinal pigment epithelial cell layer in the macula, which supports the light sensitive photoreceptor cells important to vision.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"There are currently no FDA-approved treatment options for dry AMD, so we are eager to better understand the effect that elamipretide may have in treating these roughly 13 million patients."

Duke University Center for Macular Diseases director and professor of ophthalmology and trial investigator Dr Scott Cousins said: “There are currently no FDA-approved treatment options for dry AMD, so we are eager to better understand the effect that elamipretide may have in treating these roughly 13 million patients.

“Mitochondrial dysfunction that stems from various environmental toxins may be an important causative factor in dry AMD, and in laboratory models, elamipretide appears to prevent mitochondrial dysfunction in the retinal pigment epithelium.”

The study has enrolled patients aged 55 and above who have at least one eye with intermediate AMD, and either a high-risk protein deposits (drusen) on the retina without any geographic atrophy (GA) or GA with an unaffected central fovea (non-central GA).

The secondary endpoints of the study are to determine the baseline change in physical / ophthalmic examinations and applicability of subcutaneous injections in this patient population.


Image: Back of the eye displaying intermediate AMD. Photo: courtesy of National Eye Institute of the NIH.